Acute COPD Exacerbation: Evaluation and Treatment

Bottom line

Initial workup

• Confirm the exacerbation and exclude mimics: chest radiograph, ECG, and basic labs (CBC, BMP); consider BNP or point-of-care ultrasound for heart failure or PE when the history suggests it.
• Obtain an arterial or venous blood gas when FEV1 is < 50%, SpO2 is < 90%, or there are signs of fatigue — to detect respiratory acidosis and guide the need for NIV.
• Send a sputum culture only for severe exacerbations, frequent prior antibiotics, or concern for Pseudomonas or MRSA; otherwise treat empirically per the local antibiogram.
• Assess baseline inhaler technique, vaccination status, home oxygen requirement, and recent exacerbation history for risk stratification and discharge planning.

Acute management

• Bronchodilation: give a short-acting beta-2 agonist (albuterol) with or without a short-acting anticholinergic (ipratropium) via MDI plus spacer or nebulizer, repeated every 1–4 hours per response.
• Systemic corticosteroid: prednisone 40 mg PO daily for 5 days (no taper needed) shortens recovery and improves lung function.
• Antibiotics: start if at least two of increased dyspnea, sputum volume, or purulence are present, or if hospitalization is required; doxycycline 100 mg PO every 12 hours for up to 10 days is one option — adjust to local resistance patterns.
• Controlled oxygen to maintain an SpO2 of 88–92%, titrated slowly to avoid worsening hypercapnia.
• Non-invasive ventilation for acute hypercapnic respiratory failure (pH ≤ 7.35 with an elevated PaCO2) or severe dyspnea with accessory muscle use; NIV decreases intubation and mortality.

Inpatient and longitudinal management

• Start or step up maintenance inhalers promptly — a LABA and/or LAMA; consider adding an inhaled corticosteroid to LABA/LAMA in patients with frequent exacerbations and a blood eosinophil count ≥ 300 cells/µL.
• Evaluate the need for long-term oxygen therapy before discharge (ABG or pulse oximetry on room air).
• Provide smoking-cessation counseling, ensure pneumococcal and influenza vaccination, and review inhaler technique.
• Schedule follow-up within 4 weeks of discharge to reassess symptoms, spirometry, oxygen need, and adherence.

Monitoring and disposition

• Monitor respiratory rate, SpO2, ABG (if on NIV), mental status, and hemodynamics every 2–4 hours initially.
• Reassess the need for systemic steroids daily, and convert IV to PO once stable oral intake is achieved.
• Discharge criteria: stable on a LABA/LAMA (± ICS) regimen, SpO2 ≥ 90% on baseline oxygen, able to ambulate and perform activities of daily living, competent with inhaler use, and with follow-up arranged.
• Educate on early recognition of future exacerbations and provide a written action plan.

Escalate care if

• pH < 7.25, severe acidosis, or NIV failure — prepare for endotracheal intubation and invasive mechanical ventilation.
• Hemodynamic instability, altered mental status, or an inability to clear secretions — escalate to ICU regardless of ABG values.
• Sputum grows Pseudomonas or MRSA, or the patient remains febrile after 48 hours of antibiotics — broaden coverage per sensitivities and consult Infectious Diseases.

Where guidelines disagree

Some guidelines permit systemic corticosteroid courses of up to 14 days; GOLD and the more recent ERS/ATS guidance favor a 5-day course, which is the evidence-based default used here.

Duration

Systemic steroids for 5 days; antibiotics for 5–10 days based on clinical response; bronchodilator maintenance therapy is indefinite.

Caveats

• Confirm there is no contraindication to corticosteroids (e.g., uncontrolled infection) or to doxycycline (pregnancy, intolerance) before starting.
• Use NIV cautiously with facial trauma, an inability to protect the airway, or severe hemodynamic instability.

References

1. 2025 GOLD Pocket Guide: Global Strategy for the Diagnosis, Management, and Prevention of COPD (2025) · Primary guideline“An exacerbation of COPD is defined as an event characterized by dyspnea and/or cough and sputum that worsen over < 14 days.”
2. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. · Primary guideline“Once discharged, the patient should be followed.”
3. Management of COPD exacerbations (ATS clinical resource). · Primary guideline“A meta-analysis of 21 trials of non-invasive ventilation in patients with COPD exacerbations found that non-invasive ventilation reduced the need for intubation, mortality, complications of therapy, and length of both hospital stay and ICU stay.”
4. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. (2017) · Primary guideline“For ambulatory patients having a COPD exacerbation, we suggest the administration of antibiotics (conditional recommendation, moderate quality of evidence).”